Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Income towards Parent Company: 2021-2025

Historic Income towards Parent Company for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Income towards Parent Company fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 6.57%. This contributed to the annual value of -$41.9 million for FY2024, which is 0.59% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Income towards Parent Company is -$12.1 million, which was down 23.35% from -$9.8 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Income towards Parent Company ranged from a high of $1.4 million in Q1 2021 and a low of -$22.9 million during Q4 2023.
  • For the 3-year period, SAB Biotherapeutics' Income towards Parent Company averaged around -$9.8 million, with its median value being -$9.8 million (2025).
  • As far as peak fluctuations go, SAB Biotherapeutics' Income towards Parent Company slumped by 845.93% in 2023, and later spiked by 56.50% in 2024.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Income towards Parent Company stood at -$11.6 million in 2021, then surged by 32.05% to -$7.8 million in 2022, then tumbled by 191.21% to -$22.9 million in 2023, then spiked by 56.50% to -$9.9 million in 2024, then dropped by 16.60% to -$12.1 million in 2025.
  • Its Income towards Parent Company stands at -$12.1 million for Q3 2025, versus -$9.8 million for Q2 2025 and -$10.8 million for Q1 2025.